The impact of clinical inertia on uncontrolled blood pressure in treated hypertension: real-world, longitudinal data from Japan

Satoh, Michihiro; Muroya, Tomoko; Murakami, Takahisa; Obara, Taku; Asayama, Kei; Ohkubo, Takayoshi; Imai, Yutaka; Metoki, Hirohito

doi:10.1038/s41440-023-01452-2

Hypertens Res

2023

DOI: 10.1038/s41440-023-01452-2

|View full text |Cite

The impact of clinical inertia on uncontrolled blood pressure in treated hypertension: real-world, longitudinal data from Japan

Michihiro Satoh,

Tomoko Muroya,

Takahisa Murakami

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Preface-various factors in the management of blood pressure

Mogi,

Hoshide,

Kario

2024

Hypertens Res

View full text Add to dashboard Cite

Preface-various factors in the management of blood pressure

Mogi,

Hoshide,

Kario

2024

Hypertens Res

View full text Add to dashboard Cite

Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users

Hashimoto,

Satoh,

Nakayama

et al. 2024

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo evaluate the renal prognosis of dipeptidyl peptidase‐4 inhibitor (DPP‐4i) users and non‐users using real‐world Asian data.MethodsUsing databases from DeSC Healthcare, Inc., patients aged 30 years or older who used antidiabetic drugs from 2014 to 2021 were identified. Propensity score matching analyses were used to compare renal prognosis between DPP‐4i users and non‐users. The primary outcomes were estimated glomerular filtration rate (eGFR) decline and end‐stage kidney disease (ESKD) development in the eGFR of 45 mL/min/1.73m2 or higher and eGFR of less than 45 mL/min/1.73m2 groups, respectively.ResultsIn total, 65 375 and 9866 patients were identified in the eGFR of 45 mL/min/1.73m2 or higher and eGFR of less than 45 mL/min/1.73m2 groups, respectively. In the eGFR of 45 mL/min/1.73m2 or higher group, propensity score matching created 16 002 pairs. A significant difference was observed in the primary outcome of eGFR decline between DPP‐4i users and non‐users at 2 years (−2.31 vs. −2.56 mL/min/1.73m2: difference, 0.25 mL/min/1.73m2; 95% confidence interval [CI], 0.06‐0.44) and 3 years (−2.75 vs. −3.41 mL/min/1.73m2: difference, 0.66 mL/min/1.73m2; 95% CI, 0.39‐0.93). In the eGFR less than 45 mL/min/1.73m2 group, propensity score matching created 2086 pairs. After a mean of 2.2 years of observation, ESKD development was 1.15% and 2.30% in users and non‐users, respectively, and Kaplan–Meier analysis revealed a significant difference (log rank P = .005).ConclusionsThis retrospective real‐world study revealed that patients using DPP‐4is had a better renal prognosis than those not using DPP‐4is.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The impact of clinical inertia on uncontrolled blood pressure in treated hypertension: real-world, longitudinal data from Japan

Cited by 2 publications

References 39 publications

Preface-various factors in the management of blood pressure

Preface-various factors in the management of blood pressure

Comparison of renal prognosis between dipeptidyl peptidase‐4 inhibitor users and non‐users

Contact Info

Product

Resources

About